Patients with malignancy have higher risk of developing cancer-associated thrombosis (CAT), with predominance of venous thromboembolism (VTE). CAT in these patients leads to the delay of specific cancer treatment, worse treatment outcomes and also increased mortality rates. This article is evaluating the role of direct oral anticoagulants (DOAC) in the prophylaxis and treatment of VTE in patients with CAT. The review shed the light on the newest recommendations and guidelines, according to the newest treatment guidelines, but it also discusses the potential risks of DOAC therapy in patients with CAT. Compared to the previous recommendations, in the latest clinical guidelines for the prevention and treatment of CAT, DOAC are becoming more important. However, considering that cancer patients represent a highly specific group of patients, diversification and expansion of CAT anticoagulant therapy provides personalized approach to each patient achieving more efficient and safer profile of anticoagulant therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.